FIGURE 3.

USP35 overexpression blocks erastin/RSL3‐mediated tumor suppressive effects. A, Relative USP35 mRNA level in lung cancer cell lines with or without USP35 overexpression (n = 6). B,C, Cell viability and colony formation (n = 6). D, Tumor volumes at indicating times in tumor xenografts models (n = 6). E, Tumor weights at day 25 after cell inoculation (n = 6). F,G, Cells were incubated with USP35 at a MOI of 10 or the CTRL for 12 h, and then stimulated with erastin (5 µmol/L) or RSL3 (2 µmol/L) for additional 96 h after the removal of lentiviral vectors. Cell viability and colony formation in lung cancer cell lines were determined (n = 6). H,I, Cells with or without USP35 overexpression were subcutaneously injected into the right dorsal flank of the nude mice. To induce ferroptosis in vivo, the tumor‐bearing mice were treated with erastin (15 mg/kg twice every other day) by intraperitoneal injections or RSL3 (100 mg/kg twice a week) via intratumoral injections from day 18 after cell inoculation. Tumor volumes and weights were determined at day 25 after cell inoculation (n = 6). Data are shown as mean ± SD, *P < .05 versus the matched group. NS indicates no significance